Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Chinese drug company Simcere Pharmaceutical Group
So what: Normally, a fine would be thought of as bad news, but this time investors are just happy to have the issue resolved. Jiangsu Yanshen, where Simcere holds a controlling 52.5% stake, will be fined 4.6 million renminbi for selling inferior products in addition to the 25.6 million renminbi it was fined by the Changzhou food and drug administration in May.
Now what: The fines have already been recorded in financial statements, so investors had priced in worse news, which is causing the pop today. From a performance standpoint, it is still not known when operations may continue at the plant in question. I would be leery of buying a stock with this kind of track record, but hopefully management has learned its lesson after facing individual punishments (details of the individual punishments weren't disclosed).
Interested in more info on Simcere Pharma? Add it to your watchlist.